CD8A and non-small cell lung carcinoma: Although NSCLC with low or negative PD-L1 expression is considered to show poor response to immunotherapy, the change in TME from “immune-desert” to “immune-inflamed” status with increased CD8-positive TILs prior to immunotherapy would lead to a good response to immunotherapy (31).